Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 71


SIRPαFc treatment targets human acute myeloid leukemia stem cells.

Galkin O, McLeod J, Kennedy JA, Jin L, Mbong N, Wong M, Uger RA, Minden MD, Danska JS, Wang JCY.

Haematologica. 2020 Feb 13. pii: haematol.2019.245167. doi: 10.3324/haematol.2019.245167. [Epub ahead of print] No abstract available.


Most unicompartmental knee replacement revisions could be avoided: a radiographic evaluation of revised Oxford knees in the National Joint Registry.

Kennedy JA, Palan J, Mellon SJ, Esler C, Dodd CAF, Pandit HG, Murray DW.

Knee Surg Sports Traumatol Arthrosc. 2020 Feb 10. doi: 10.1007/s00167-020-05861-5. [Epub ahead of print]


The clinical outcomes of cementless unicompartmental knee replacement in patients with reduced bone mineral density.

Mohammad HR, Kennedy JA, Mellon SJ, Judge A, Dodd CA, Murray DW.

J Orthop Surg Res. 2020 Jan 31;15(1):35. doi: 10.1186/s13018-020-1566-2.


Long-term in vivo wear of different bearing types used for the Oxford Unicompartmental Knee Replacement.

Mohammad HR, Campi S, Kennedy JA, Judge A, Murray DW, Mellon SJ.

Bone Joint Res. 2019 Dec 3;8(11):535-543. doi: 10.1302/2046-3758.811.BJR-2019-0163.R1. eCollection 2019 Nov.


Ten-year clinical and radiographic results of 1000 cementless Oxford unicompartmental knee replacements.

Mohammad HR, Kennedy JA, Mellon SJ, Judge A, Dodd CA, Murray DW.

Knee Surg Sports Traumatol Arthrosc. 2019 Jun 17. doi: 10.1007/s00167-019-05544-w. [Epub ahead of print]


New Instrumentation Improves Patient Satisfaction and Component Positioning for Mobile-Bearing Medial Unicompartmental Knee Replacement.

Malhotra R, Kumar V, Wahal N, Clavé A, Kennedy JA, Murray DW, Pandit H.

Indian J Orthop. 2019 Mar-Apr;53(2):289-296. doi: 10.4103/ortho.IJOrtho_172_17.


The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes.

McNamara CJ, Panzarella T, Kennedy JA, Arruda A, Claudio JO, Daher-Reyes G, Ho J, Siddiq N, Devlin R, Tsui H, Su J, Stockley T, Sukhai M, Kanwar N, Chan S, Maze D, Schimmer A, Schuh A, Sibai H, Viswabandya A, Yee K, Minden MD, Kamel-Reid S, Gupta V.

Blood Adv. 2018 Oct 23;2(20):2658-2671. doi: 10.1182/bloodadvances.2018021469.


Distinct patterns of clonal evolution in patients with concurrent myelo- and lymphoproliferative neoplasms.

Kennedy JA, Medeiros JJF, Dobson SM, Arruda A, Sukhai MA, Stockley T, Tierens A, Minden MD, Kamel-Reid S, Dick JE, Gupta V.

Blood. 2018 Nov 15;132(20):2201-2205. doi: 10.1182/blood-2018-04-845065. Epub 2018 Sep 24. No abstract available.


Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice.

Fink EC, McConkey M, Adams DN, Haldar SD, Kennedy JA, Guirguis AA, Udeshi ND, Mani DR, Chen M, Liddicoat B, Svinkina T, Nguyen AT, Carr SA, Ebert BL.

Blood. 2018 Oct 4;132(14):1535-1544. doi: 10.1182/blood-2018-05-852798. Epub 2018 Jul 31.


Age and Outcomes of Medial Meniscal-Bearing Unicompartmental Knee Arthroplasty.

Kennedy JA, Matharu GS, Hamilton TW, Mellon SJ, Murray DW.

J Arthroplasty. 2018 Oct;33(10):3153-3159. doi: 10.1016/j.arth.2018.06.014. Epub 2018 Jun 20.


Clinical Utility of Next-generation Sequencing in the Management of Myeloproliferative Neoplasms: A Single-Center Experience.

Alduaij W, McNamara CJ, Schuh A, Arruda A, Sukhai M, Kanwar N, Thomas M, Spiegel J, Kennedy JA, Stockley T, Tsui H, Devlin R, Sibai H, Maze D, Schimmer A, Yee K, Chan S, Kamel-Reid S, Gupta V.

Hemasphere. 2018 May 4;2(3):e44. doi: 10.1097/HS9.0000000000000044. eCollection 2018 Jun.


Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making.

Kennedy JA, Hobbs G.

Curr Hematol Malig Rep. 2018 Jun;13(3):202-211. doi: 10.1007/s11899-018-0449-7. Review.


Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy.

Spiegel JY, McNamara C, Kennedy JA, Panzarella T, Arruda A, Stockley T, Sukhai M, Thomas M, Bartoszko J, Ho J, Siddiq N, Maze D, Schimmer A, Schuh A, Sibai H, Yee K, Claudio J, Devlin R, Minden MD, Kamel-Reid S, Gupta V.

Blood Adv. 2017 Sep 8;1(20):1729-1738. doi: 10.1182/bloodadvances.2017009530. eCollection 2017 Sep 12.


Early years postgraduate surgical training programmes in the UK are failing to meet national quality standards: An analysis from the ASiT/BOTA Lost Tribe prospective cohort study of 2,569 surgical trainees.

Writing group; Project steering group; ASiT/BOTA Lost Tribe Study Group.

Int J Surg. 2018 Apr;52:376-382. doi: 10.1016/j.ijsu.2017.09.074. Epub 2017 Oct 14.


Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias.

Gibson CJ, Kennedy JA, Nikiforow S, Kuo FC, Alyea EP, Ho V, Ritz J, Soiffer R, Antin JH, Lindsley RC.

Blood. 2017 Jul 6;130(1):91-94. doi: 10.1182/blood-2017-01-764951. Epub 2017 Apr 26. No abstract available.


Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome.

Kennedy JA, Ebert BL.

J Clin Oncol. 2017 Mar 20;35(9):968-974. doi: 10.1200/JCO.2016.71.0806. Epub 2017 Feb 13. Review.


A 17-gene stemness score for rapid determination of risk in acute leukaemia.

Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, Arruda A, Popescu A, Gupta V, Schimmer AD, Schuh AC, Yee KW, Bullinger L, Herold T, Görlich D, Büchner T, Hiddemann W, Berdel WE, Wörmann B, Cheok M, Preudhomme C, Dombret H, Metzeler K, Buske C, Löwenberg B, Valk PJ, Zandstra PW, Minden MD, Dick JE, Wang JC.

Nature. 2016 Dec 15;540(7633):433-437. doi: 10.1038/nature20598. Epub 2016 Dec 7.


Understanding the Relationship between Red Wine Matrix, Tannin Activity, and Sensory Properties.

Watrelot AA, Byrnes NK, Heymann H, Kennedy JA.

J Agric Food Chem. 2016 Nov 30;64(47):9116-9123. Epub 2016 Nov 16.


Effects of Leaf Removal and Applied Water on Flavonoid Accumulation in Grapevine (Vitis vinifera L. cv. Merlot) Berry in a Hot Climate.

Yu R, Cook MG, Yacco RS, Watrelot AA, Gambetta G, Kennedy JA, Kurtural SK.

J Agric Food Chem. 2016 Nov 2;64(43):8118-8127. Epub 2016 Oct 19.


miR-126 Regulates Distinct Self-Renewal Outcomes in Normal and Malignant Hematopoietic Stem Cells.

Lechman ER, Gentner B, Ng SWK, Schoof EM, van Galen P, Kennedy JA, Nucera S, Ciceri F, Kaufmann KB, Takayama N, Dobson SM, Trotman-Grant A, Krivdova G, Elzinga J, Mitchell A, Nilsson B, Hermans KG, Eppert K, Marke R, Isserlin R, Voisin V, Bader GD, Zandstra PW, Golub TR, Ebert BL, Lu J, Minden M, Wang JCY, Naldini L, Dick JE.

Cancer Cell. 2016 Apr 11;29(4):602-606. doi: 10.1016/j.ccell.2016.03.015. No abstract available.

Supplemental Content

Loading ...
Support Center